Announcements Trials
Browse Landscape

Phase

Phase 4 3Phase 2 2Phase 3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Myeloid 1

Conditions

Lymphoma 4Leukemia 4Hyperuricemia 4Leukemia, Myeloid, Acute 3Tumor Lysis Syndrome 2Burkitt Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Nutritional and Metabolic Diseases 1Myelodysplastic Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Congenital Abnormalities 1Blast Crisis 1

Interventions

rasburicase 2Allopurinol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Tumor Lysis Syndrome × rasburicase × Clear all
NCT01200485 2020-01-31

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

M.D. Anderson Cancer Center

Phase 2 Completed
55 enrolled 11 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT00628628 2013-08-01

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 2 Completed
82 enrolled 6 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Tumor Lysis Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡